000131689 001__ 131689
000131689 005__ 20241125101140.0
000131689 0247_ $$2doi$$a10.1093/ijnp/pyad051
000131689 0248_ $$2sideral$$a137048
000131689 037__ $$aART-2023-137048
000131689 041__ $$aeng
000131689 100__ $$aHidalgo-Figueroa, Maria
000131689 245__ $$aAssociation of prolactin, oxytocin, and homocysteine with the clinical and cognitive features of a first episode of psychosis over a 1-year follow-up
000131689 260__ $$c2023
000131689 5060_ $$aAccess copy available to the general public$$fUnrestricted
000131689 5203_ $$aBackground: The clinical debut of schizophrenia is frequently a first episode of psychosis (FEP). As such, there is considerable interest in identifying associations between biological markers and clinical or cognitive characteristics that help predict the progression and outcome of FEP patients. Previous studies showed that high prolactin, low oxytocin, and high homocysteine are factors associated with FEP 6 months after diagnosis, at which point plasma levels were correlated with some clinical and cognitive characteristics.
Methods: We reexamined 75 patients at 12 months after diagnosis to measure the evolution of these molecules and assess their association with clinical features.
Results: At follow-up, FEP patients had lower prolactin levels than at baseline, and patients treated with risperidone or paliperidone had higher prolactin levels than patients who received other antipsychotic agents. By contrast, no changes in oxytocin and homocysteine plasma levels were observed between the baseline and follow-up. In terms of clinical features, we found that plasma prolactin and homocysteine levels were correlated with the severity of the psychotic symptoms in male FEP patients, suggesting that they might be factors associated with psychotic symptomatology but only in men. Together with oxytocin, these molecules may also be related to sustained attention, verbal ability, and working memory cognitive domains in FEP patients.
Conclusion: This study suggests that focusing on prolactin, oxytocin, and homocysteine at a FEP may help select adequate pharmacological treatments and develop new tools to improve the outcome of these patients, where sex should also be borne in mind.
000131689 536__ $$9info:eu-repo/grantAgreement/ES/MICIU-ISCIII-FEDER/PI19-00766$$9info:eu-repo/grantAgreement/ES/MINECO-ISCIII-FEDER/PI11-00325
000131689 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000131689 590__ $$a4.5$$b2023
000131689 592__ $$a1.525$$b2023
000131689 591__ $$aCLINICAL NEUROLOGY$$b42 / 280 = 0.15$$c2023$$dQ1$$eT1
000131689 593__ $$aPharmacology$$c2023$$dQ1
000131689 591__ $$aPSYCHIATRY$$b45 / 279 = 0.161$$c2023$$dQ1$$eT1
000131689 593__ $$aPsychiatry and Mental Health$$c2023$$dQ1
000131689 591__ $$aPHARMACOLOGY & PHARMACY$$b60 / 354 = 0.169$$c2023$$dQ1$$eT1
000131689 593__ $$aPharmacology (medical)$$c2023$$dQ1
000131689 591__ $$aNEUROSCIENCES$$b70 / 310 = 0.226$$c2023$$dQ1$$eT1
000131689 594__ $$a8.4$$b2023
000131689 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000131689 700__ $$aSalazar, Alejandro
000131689 700__ $$aRomero-López-Alberca, Cristina
000131689 700__ $$aMacDowell, Karina S
000131689 700__ $$aGarcía-Bueno, Borja
000131689 700__ $$aBioque, Miquel
000131689 700__ $$aBernardo, Miquel
000131689 700__ $$aParellada, Mara
000131689 700__ $$aGonzález-Pinto, Ana
000131689 700__ $$aGarcía-Portilla, M Paz
000131689 700__ $$0(orcid)0000-0003-3025-8048$$aLobo, Antonio$$uUniversidad de Zaragoza
000131689 700__ $$aRodriguez-Jimenez, Roberto
000131689 700__ $$aBerrocoso, Esther
000131689 700__ $$aLeza, Juan C
000131689 700__ $$a
000131689 7102_ $$11003$$2027$$aUniversidad de Zaragoza$$bDpto. Anatom.Histolog.Humanas$$cArea Anatom.Embriol.Humana
000131689 773__ $$g26, 11 (2023), 796-807$$pInt. j. neuropsychopharmacol.$$tINTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY$$x1461-1457
000131689 8564_ $$s964745$$uhttps://zaguan.unizar.es/record/131689/files/texto_completo.pdf$$yVersión publicada
000131689 8564_ $$s3097777$$uhttps://zaguan.unizar.es/record/131689/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000131689 909CO $$ooai:zaguan.unizar.es:131689$$particulos$$pdriver
000131689 951__ $$a2024-11-22-12:02:30
000131689 980__ $$aARTICLE